ClinicalTrials.gg
Not yet recruitingNCT07265752Updated Oct 9, 2026

Tirzepatide for the Treatment of Cannabis Use Disorder

A Phase 2 interventional study of Tirzepatide and Placebo in Cannabis Use Disorder, sponsored by Brigham and Women's Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder.

Read the detailed description

This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder. Eligible participants will be scheduled in random order to receive either tirzepatide or placebo injection in double-blind fashion and cross-over design. Outcomes will be assessed at the following study visit. Washout period of at least 4 weeks will be required between tirzepatide or placebo injections. Primary outcome of interest is cue-induced craving to cannabis-related visual cues.

02

Conditions studied

  • Cannabis Use Disorder

Keywords

  • tirzepatide
03

In context

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,269 studies on the registry; 230 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English speaking adults aged 18 and above
  • Diagnosed with cannabis use disorder, severe

Exclusion criteria

Exclusion Criteria:

  • Active psychosis, active suicidality or homicidality or any psychiatric condition that impair ability to provide
  • Any current or lifetime diagnosis of eating disorders including anorexia, bulimia, binge eating or
  • Comorbid substance use disorder
  • \<21 kg/m2
  • Current or lifetime diagnosis of Type 1 or Type 2 diabetes
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • Use of any glucagon-like peptide -1 agonist medications in the prior 3 months
  • Anticipating receipt of any glucagon-like peptide-1 agonist medications during the trial
  • Current hypoglycemia as indicated by a blood sugar level of \<71 mg/dL measured at baseline visit, as well as visits 2 and 4.
  • Untreated cholelithiasis or gallbladder disease
  • History of acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or congestive heart failure in the last 90 days
  • Systolic blood pressure persistently above 160 mmHg or diastolic blood pressure persistently above 100 mmHg during screening
  • History of inflammatory bowel disease, bariatric surgery, pancreatitis, diabetic gastroparesis, or non-arteritic anterior ischemic optic neuropathy
  • Liver function test greater than 3 times upper normal limit
  • Renal impairment as indicated by estimated (eGFR) of \<30
  • History of or allergy to tirzepatide
  • Pregnant or breastfeeding
  • Individuals taking glucagon-like peptide-1 agonists or other weight loss drugs.
  • Anticipated to participate in a concurrent drug trial
  • Any other reason or clinical condition that the investigators judge may interfere with study participation and/or be unsafe for a participant
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    tirzepatide

    2.5mg subcutaneous injection once

    Drug: Tirzepatide

  • Placebo comparator
    placebo

    matching placebo subcutaneous injection once

    Drug: Placebo

Interventions

  • 2.5mg subcutaneous injection once

  • DrugPlacebo

    Saline placebo subcutaneous injection once

06

What researchers measure

Primary outcomes

  1. Cue-Induced Craving

    Craving scores will be assessed using a cue-reactivity paradigm in which participants are exposed to cannabis\]-related cues. Scores range from 0 to 30, with higher scores indicating greater craving intensity.

    Time frame: 5 weeks

Secondary outcomes

  1. Serious adverse event

    Incidence of serious adverse events

    Time frame: 5 weeks

  2. Cravings

    Cannabis craving scale using the 12-item questionnaire, each item scored on a 1-7 sale. Higher scores (either average or summed) indicates stronger cravings.

    Time frame: 5 weeks

  3. Abstinence

    Percent days abstinent from cannabis

    Time frame: 5 weeks

  4. Weight

    Weight

    Time frame: 5 weeks

  5. Blood sugar

    Blood glucose

    Time frame: 5 weeks

  6. Hemoglobin A1c

    Hemoglobin A1c

    Time frame: 5 weeks

  7. Depression severity as measured by the Patient Health Questionnaire-8 (PHQ-8)

    Depression severity as measured by the Patient Health Questionnaire-8 (PHQ-8). The PHQ-8 assesses depression severity over the past two weeks. Total scores range from 0 to 24, with higher scores indicating greater depression severity (worse outcome). Score interpretation: 0-4 (none), 5-9 (mild), 10-14 (moderate), 15-19 (moderately severe), 20-24 (severe depression).

    Time frame: 5 weeks

  8. Anxiety severity as measured by the Generalized Anxiety Disorder-7 scale (GAD-7)

    The GAD-7 assesses anxiety symptom severity over the past two weeks. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity (worse outcome). Score interpretation: 0-4 (minimal anxiety), 5-9 (mild), 10-14 (moderate), 15-21 (severe anxiety).

    Time frame: 5 weeks

  9. Suicidality as measured by the C-SSRS (Columbia-Suicide Severity Rating Scale)

    The C-SSRS assesses the presence and severity of suicidal ideation and behavior. Suicidal ideation severity scores range from 0 to 5 (0=no ideation, 1=wish to be dead, 2=non-specific active suicidal thoughts, 3=active suicidal ideation with methods, 4=suicidal intent, 5=suicidal intent with plan), with higher scores indicating greater severity (worse outcome). The scale also captures suicidal behavior as binary yes/no responses.

    Time frame: 5 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Jun 2028, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 5, 2025
StartEst.
Mar 1, 2027
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07265752
Responsible party
Joji Suzuki, MD (Principal Investigator, Division of Addiction Treatment and Prevention, AMC Psychiatry Mass General Brigham, Brigham and Women's Hospital) — Principal investigator
First posted
Dec 5, 2025
Start date
Mar 1, 2027 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Mary R Shen, MD
Contact
mshen4@bwh.harvard.edu
6177325752
Joji Suzuki
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion